Geraldine Maro

Prior to joining Adivo, Géraldine was a neuroscientist at Stanford University (USA) and at the Ecole Normale Supérieure (France), two world leading research institutions. In this role she managed international collaborative projects and co-authored a number of publications in top ranking journals. Her research focused on the cellular and molecular mechanisms that underlie neurological diseases such as ALS or autism. In addition, Géraldine has interacted with a number of healthcare industry players through her work with SIRUM, a nonprofit startup that uses technology to connect surplus drugs with the needs of safety-net clinics. Since 2010, SIRUM has helped redistribute more than $50M worth of drugs, enough to fill over 500,000 prescriptions for patients in the US. Géraldine currently chairs SIRUM’s Board of Directors. Géraldine’s extensive experience in biomedical sciences and healthcare allows her to quickly grasp and disseminate new information, and pull insights from complex data. At Adivo Associates, she has led projects on market intelligence, market forecasting, competitive intelligence and health economics and outcome research projects in various therapeutic areas, including Hemophilia, Immunodeficiency Diseases and Autoimmune Diseases. Throughout her work, Géraldine has been committed to deliver data-driven, sound and innovative solutions to her clients. Géraldine holds a PhD in Developmental Biology from the Ecole Normale Supérieure (Paris), as well as a Master’s in Cellular and Molecular Biology from the Ecole Normale Supérieure (Lyon).